Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, et al. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2021 Jun 14. pii: 10.1007/s10549-021-06197.
PMID: 34125340